Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
12/09 - New disappointing results from a trial of adjuvant immunotherapy for patients with renal cell carcinoma who underwent nephrectomy contrast with those from a previous trial that showed benefit with another agent.
The new results, from CheckMate 914, show that adjuvant treatment with the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) did not improve disease-free survival (DFS) compared with placebo.
The finding was presented here at the European Society for Medical Oncology (ESMO) Annual Meeting 2022 in Paris, France.
CheckMate 914 "did not meet the primary endpoint," study presenter Robert J. Motzer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York City, told a press conference.
Wilt u de rest van dit artikel lezen?
Registreer gratis om toegang te krijgen tot de volledige inhoud van MediQuality op al uw schermen